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The main purpose of the study was to help establish the best dose regimen of 
hyperbaric bupivacaine, when combined with intrathecal fentanyl, for spinal 
anaesthesia for brachytherapy for carcinoma of the cervix. This procedure is 
performed as a day case at Groote Schuur Hospital.   
 
It was therefore decided to compare what may be considered as a conventional dose 
of hyperbaric bupivacaine with a lower dose, both combined with fentanyl 15 ug for 
spinal anaesthesia. The lower dose would hopefully allow for adequate anaesthesia, 
with less motor block and a shorter time to complete recovery, the latter being the 
primary outcome measure. This would have a significant advantage for ambulatory 
surgery.  
 
Patients and methods 
 
The study was a prospective, randomised, double-blinded trial. Ethics approval was 
sought and granted from the University of Cape Town Human Research Ethics 
Committee prior to patient enrolment for the study. Written, informed patient consent 
was given in every case. All patients attending the oncology clinic for brachytherapy 
for carcinoma of the cervix were assessed for inclusion in the study. Exclusion criteria 
were a contra-indication to spinal anaesthesia or an unwillingness to take part in the 
study.   
 
Forty patients were randomized by sealed envelope to receive a dose of either 1 ml of 
hyperbaric bupivacaine 0.5% (5 mg) vs 1.8 ml hyperbaric bupivacaine (9 mg) both 
with fentanyl 15 ug, via the L3/4 interspace. Both the patients as well as the 
anaesthetist recording and collecting the clinical data were blinded to the group 



















The time to achieve hospital discharge criteria was significantly shorter in the Low 
Dose (LD) group (mean time of 235 [206-264] minutes) versus the High Dose (HD) 
group (mean time of 280 [263-297] minutes) (p < 0.01). Patients in the LD group 
were also eligible for discharge from the recovery area in a shorter time (p < 0.01). 
Although there was significantly less motor block in the LD group (p < 0.001), patient 
satisfaction regarding motor block was the same in the two groups (p = 0.96). There 
was a trend towards more inadequate (unsatisfactory) spinal blocks in the low dose 




The trend towards a larger number of patients with failed spinal anaesthesia in the low 
dose group was a concern, and in an adequately powered study examining quality of 
analgesia, this could have achieved statistical significance. This trend towards more 
failed spinal anaesthesia in the low dose group was despite an acceptable median peak 
sensory level (to cold ethyl chloride spray) of T8 for the required surgery (IQR of T8-
T10). This suggests that the quality of surgical anaesthesia for any given procedure 
cannot be predicted entirely by the dermatomal spread of local anaesthetic (or peak 




Our study suggests that a dose closer to- or equivalent to that of the high dose group 
may be preferable, to ensure consistent and reliable spinal anaesthesia in this patient 
population presenting for ambulatory surgery. More studies are needed to find the 


















DISSERTATION IN PUBLICATION-READY FORMAT 
 
Part A:  The Research Protocol 
 
Spinal anaesthesia for brachytherapy for carcinoma of the cervix: a 
comparison of two dose regimens of hyperbaric bupivacaine 
 




Spinal anaesthesia (SA) can be suitably performed for a variety of outpatient 
procedures.  Time taken for fitness to discharge home from hospital is an important 
consideration, as it impacts not only on patient satisfaction, but also on human and 
financial resource constraints within a hospital.  The main goal is to use the lowest 
dose of local anaesthetic for adequate anaesthesia.  This allows for the shortest 
recovery time for ambulatory surgery. [1] This study was undertaken to establish the 
best regimen for spinal anaesthesia for brachytherapy in carcinoma of the cervix.  
Patients undergo insertion of an intra-cervical stent which is 8 mm in diameter.  This 
stent facilitates the subsequent introduction of an applicator necessary to perform 
brachytherapy (immediate-proximity radiotherapy).  The insertion of the intra-
cervical stent is especially painful as the cervical anatomy is distorted to varying 
degrees by malignant tumour. The procedure also involves probing (“sounding”) of 
the fundus of the uterus.  Therefore the height of the spinal block should extend at 
least to the T10 level and include all the lumbar and sacral dermatomes.   
 
The duration of the procedure (and hence required duration of anaesthesia) may be 
greater than 1 hour and even as long as 80 minutes in some cases, so that the short 
duration of action of lidocaine makes it unsuitable. Furthermore, concerns regarding a 
significant incidence of transient neurological deficits after lidocaine spinal 
anaesthesia have resulted in a preference for bupivacaine, despite its long duration of 
action.[2]  Hyperbaric bupivacaine, administered at the L3-4 level, was considered 













within the cerebro-spinal fluid (CSF) in the supine position, in order to block the 
required dermatomal levels (T10-S4).[3-5] In addition, plain bupivacaine may be 
associated with a greater duration of motor block than the hyperbaric formulation. [6]   
 
When combined with a small dose of short-acting lipophilic opioid such as fentanyl, 
sensory block is intensified without a significant increase in side-effects. This allows 
a reduction in bupivacaine dose and hence less motor blockade. [7] Although fentanyl 
may cause a minor increase in the time taken for regression of sensory block, a small 
dose does not cause urinary retention or significantly prolong the time taken to 
achieve discharge criteria. [8] 
 
It was therefore decided to compare a conventional dose of bupivacaine and fentanyl 
for SA, with a lower dose regimen, the composition of which would allow for 
adequate anaesthesia and a shorter time to complete recovery. The primary outcome 
variable will be the time taken to achieve criteria for hospital discharge. Secondary 
outcomes will include patient satisfaction scores, based upon quality of anaesthesia 
and motor block (appendix C). The findings should contribute to the establishment of 
an anaesthesia management protocol for this specific procedure. 
 
Patients and methods 
 
This proposed study is a prospective, randomized, double-blinded trial.  After 
approval from the Faculty of Health Sciences Human Ethics Committee of the 
University of Cape Town, informed consent will be obtained in the patient’s first 
language, inside a quiet, private clinic room during the consultation with the 
consultant radiotherapist Dr van Wyk on the day prior to the brachytherapy (see 
appendix D for the English version, compiled according to the Standard Operating 
Procedures published by the UCT HREC). All patients attending the radiotherapy 
clinic scheduled for brachytherapy for carcinoma of the cervix will be included in the 
enrolment process. The only exclusion criteria will be a contra-indication to spinal 
anaesthesia, or unwillingness from the patient to take part in the study.  
 
Regarding the informed consent process, an interpreter will be available to assist with 













the original document will be made.  The original will be placed in the trial records 
and one copy placed in the patient’s medical records.  The other copy will be given to 
the patient for reference.  The “Consort Statement (2010) Flow Diagram” (see 
appendices) will be used in order to help lend credibility to the study and allow us to 
reflect on the processes of enrolment, allocation, study intervention and analysis.  
 
Forty patients will be randomised by sealed envelope to receive a subarachnoid dose 
of either 1 ml of hyperbaric bupivacaine 0.5% (5mg) plus 15 µg fentanyl (Group LD, 
n=20), or 1.8 ml hyperbaric bupivacaine 0.5% (9 mg) plus 15 µg fentanyl (Group SD, 
n=20), via the L3/4 interspace, for brachytherapy for carcinoma of the cervix. The 
anaesthetist collecting the data during the procedure will not be the anaesthetist who 
performed the spinal anaesthetic, so that blinding is ensured.    
 
On the day of surgery, patients will receive no pre-medication.  An 18 gauge cannula 
will be inserted for intravenous (IV) access. Standard monitoring (pulse oximeter, 
non-invasive blood pressure and ECG) will be applied, prior to sitting the patient 
upright for SA. Baseline blood pressure will be calculated as the mean of two systolic 
blood pressures measured at rest during the 5 minutes prior to spinal anaesthesia. SA 
will be administered in the sitting position, via the L3/4 interspace, using a 25 gauge 
Whitacre spinal needle. The dose will be injected over 10-15 seconds. The patient will 
remain sitting for 2 minutes after the injection is complete and then be re-positioned 
to lie supine at first, followed by the lithotomy position for the duration of the 
procedure. The anaesthetist performing the postoperative assessment will be blinded 
to the group allocation. Intravenous midazolam 0.025 mg/kg (maximum of 2 mg) will 
be administered, unless the patient is over 65 years of age. The investigators believe 
that this relatively small dose of midazolam is unlikely to have a significant effect on 
memory recall and therefore not bias the results of the patient questionnaire. 
 
Lactated Ringer’s solution 500 ml will be used for co-loading. Blood pressure will be 
measured every 3 minutes after induction of anaesthesia. A decrease in systolic blood 















The dermatomal level of the sensory block will be measured using cold sensitivity to 
ethyl chloride spray, but not assessed using light touch. In order to reduce possible 
inter-observer variability and increase clinical precision (or reproducibility) when 
assessing dermatomal level of block, the following method will be employed by every 
clinician collecting the data. The level of the block will be assessed starting from the 
dermatomes above the level of the block. The level at which any decrease in cold 
sensitivity is first reported will be regarded as the dermatomal level of sensory block. 
The level of sensory block will initially be assessed every 5 minutes until the height 
of the block has remained the same for 3 consecutive readings, i.e. until the sensory 
block is fully established. It will then be measured every 10 minutes until there has 
been a regression in sensory block of 2 dermatomes, and then every 15 minutes until 
all of the hospital discharge criteria are met. Time taken to eligibility for discharge 
from the theatre recovery area (sensory level T10 or lower, together with 
cardiovascular stability) will be noted. 
 
Planned management in the case of failed or inadequate SA: if no sensory block is 
achieved, the patient will receive general anaesthesia. If there is evidence that an 
adequate sensory block has been achieved, the patient will be asked to grade their 
level of discomfort after initiation of the surgical procedure. The sensation 
experienced by the patient during the procedure will be assessed and categorized into 
one of 4 groups (appendix A). If the patient falls into group 1-3, the quality of pain 
control will be deemed adequate and the surgical procedure will continue without 
giving any supplemental analgesia or converting to a general anaesthetic.  
 
If, however, the patient is experiencing pain and requests additional pain relief upon 
being offered it, or is in obvious need of additional analgesia, the patient will be 
allocated to group 4 and the SA regarded as inadequate for the planned surgical 
procedure. The attending anaesthetist will then give additional analgesia to 
supplement SA. This will consist either of intravenous fentanyl or conversion to 
general anaesthesia.  
 
Data collection and entry   
 













format. EpiData Analysis and/or Stata (Stata/IC 12.1, StataCorp, LP, 4905 Lakeway 
Drive, College Station, TX 77845, USA) statistical programs will then be used to 




The Null hypothesis is that there is no difference in time to eligibility for hospital 
discharge following injection of either of the spinal solutions.   
 
Calculating sample size 
 
The following time sequences are expected, based upon literature review. [1, 7, 8] 
Time taken for eligibility for hospital discharge in the lower dose (LD) group (Mean 
[SD]) = 195 [50] minutes, and in the higher dose group 275 [50] minutes. 
 
Using the means calculated from clinical data collected before the study (called our 
“pilot study”), which were 195 and 250 minutes for the 2 groups respectively, with a 
standard deviation of 50 minutes, the statistical program Stata (Stata/IC 12.1, 
StataCorp, LP, 4905 Lakeway Drive, College Station, TX 77845, USA) calculated 
that 18 patients would be needed in each group for a power of 90%.  This was 
confirmed by a sample size and analysis statement from PASS (Power analysis and 
sample size 2008) which suggests that Group sample sizes of 18 and 18 achieve 91% 
power to detect a difference of -55.0 between the null hypothesis that both group 
means are 195 minutes and the alternative hypothesis that the mean of group 2 is 250 
minutes, with known group standard deviations of 50 minutes and with a significance 
level (alpha) of 0.05 using a two-sided Mann-Whitney test. We have therefore 




Histograms and/or box-and-whisker plots will be used to depict numerical data, and 
frequency tables for categorical data.  The “Shapiro-Wilk” test will indicate whether 














The following statistical tests will be employed: 
 
i) For numerical data 
 
- Statistical analysis of the primary outcome variable, namely time taken to 
achieve criteria for hospital discharge, will employ the Student’s t-test, or 
otherwise Mann-Whitney U-test if appropriate. All other time comparisons 
will employ ANOVA for repeated measures 
 
- Group demographic data will be analysed separately using the Student’s t-test, 
except for the ASA rating which will employ the Mann-Whitney U-test 
 
- Inter-group differences in dermatomal levels of sensory block (including peak 
dermatomal level achieved) will be analysed using the Mann-Whitney U-test, 
as this data does not follow a normal distribution 
 
ii) For categorical data: 
 
- Quality of analgesia (appendix A) will be grouped into either satisfactory 
anaesthesia (scores 1-3) or unsatisfactory anaesthesia (a score of 4). A Fisher’s 
exact test will then be employed to detect any inter-group differences 
 
-  The degree of motor block (according to the modified Bromage scale, 
appendix B) will be compared using the Chi-squared test  
 
- To detect any possible differences between the 2 groups regarding the 3 
questions being asked in the  patient satisfaction questionnaire (appendix C), 




The primary outcome variable will be the time taken to achieve criteria for discharge 














1) Regression of sensory block to S2 sensory level 
2) Ability to walk unaided 
3) Ability to void unaided 
 
Secondary outcomes will include a patient satisfaction score. A visual analogue score 
will be used to assess satisfaction with quality of anaesthesia and motor block. The 
following data will be collected for comparison: 
 
- The highest (peak) dermatomal level of sensory blockade achieved 
- Time taken to reach this peak sensory level 
- Sensation felt by the patient during the procedure (appendix A) 
- Modified Bromage Scale of motor blockade at the time of peak sensory 
blockade (appendix B) 
- Time to eligibility for discharge from theatre recovery area 
- Time to 2-segment regression of sensory block 
- Time taken for sensory block to regress to dermatomal level S2 
- Time taken to walk unaided 
- Time taken to void unaided 
-     Side effects: 
- nausea and/or vomiting 
- pruritus 
- light-headedness or dizziness 
-    Blood pressure (baseline, immediately prior to spinal anaesthesia, then at 2 
minutes, at 5 minutes, and every 5 minutes thereafter until 60 minutes after 
induction of spinal anaesthesia) 
-    Vasopressor requirement 
 
Follow up will be done after one week by the radiotherapist, who will inquire about 
post-operative headache or radicular pain (i.e. pain not related to the operative site, 
but in the buttocks, thighs or lower limbs) which may be as a result of the spinal 
anaesthetic given.  Patients will be encouraged to report any symptoms experienced in 















Addendum:  “Pilot study” 
 
During 2008 – 2009 the principal investigator undertook a small pilot study, as part of 
routine clinical practice, to assess the feasibility of the study.  In summary, data was 
collected on 16 female patients between 23-78 years of age, ASA grades 1-3.  Clinical 
outcomes were assessed using doses of between 0.5-1.8 ml of hyperbaric bupivacaine 
0.5%, combined with either 15 or 20 µg of fentanyl.  No patients required conversion 
to general anaesthesia, and none required IV supplementation of analgesia. Some 
patients who received less than 1.0 ml of hyperbaric bupivacaine 0.5% with fentanyl 
15 µg experienced some discomfort, but declined supplementary analgesia when 
offered. Time taken for regression of sensory block to level S2 varied between 190 – 
200 min for 1 ml of hyperbaric bupivacaine 0.5% and between 240 – 250 min for 
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A: Quality of analgesia 
 
1- Complete absence of any sensation 
2- Sensation of motion only 
3- Mild discomfort, but declining offer for additional analgesia 
4- Patient requests additional analgesia / in obvious need of additional analgesia 
 
 
B: Modified Bromage scale [9] 
 
0 = Full leg movement (full flexion of knees and ankles) 
1 = Inability to raise extended legs, just able to flex knees, full ankle flexion 
2 = Inability to flex knees, some flexion of ankles possible 























C:  Patient questionnaire 
 (VAS - completed on the day of surgery, once eligible for hospital discharge) 
 
1) How satisfied are you, overall, with the spinal anaesthetic you received for your 
surgical procedure?  
(Mark the spot on the line below that best describes your experience) 
 
______________________________________________________________ 
0 1 2 3 4 5 6 7 8 9 10 
Completely   A little   Reasonably      Completely 
Dissatisfied   dissatisfied  satisfied          Satisfied 
 
If you marked a value below 5, please say why: _________________________ 
 
2) How satisfied are you with the amount of pain/discomfort you felt during the 
surgical procedure?  
(Mark the spot on the line below that best describes your experience) 
 
______________________________________________________________ 
0 1 2 3 4 5 6 7 8 9 10 
Completely   A little   Reasonably      Completely 
Dissatisfied   dissatisfied  satisfied          Satisfied 
 
If you marked a value below 5, please say why: _________________________ 
 
3) How satisfied are you with the amount of weakness in your legs experienced 
during and after the procedure? 
(Mark the spot on the line below that best describes your experience) 
 
______________________________________________________________ 
0 1 2 3 4 5 6 7 8 9 10 
Completely   A little   Reasonably      Completely 
Dissatisfied   dissatisfied  satisfied          Satisfied 
 













Appendix D:  Patient Information and Informed Consent 
 
 
Study Title: Spinal anaesthesia for brachytherapy for carcinoma of the 
cervix: a comparison of two dose regimens of hyperbaric 
bupivacaine 
 
Principal Investigators: N Haus, RA Dyer  (Contact no. 021 404 5001/3) 
UCT Human Research Ethics Committee (HREC) Ref no: 421/2010 






You are invited to take part in this study.  Before you decide whether or not to take 
part in the study, you should fully understand what is involved.  After reading and 
having had this information properly explained to you, if you have anything you 
would like to know or questions you would like to ask, please feel free to discuss 
these with either the doctor taking you through this consent process, or the main 
researchers mentioned above.   
 
 
Why is this study being performed? 
 
We have decided to compare 2 different doses of a local anaesthetic called 
bupivacaine.  This local anaesthetic is given to you when the anaesthetic doctor gives 
you a spinal anaesthetic.  We want to see if the one dose is better than the other dose, 




Why are you being asked to take part? 
 
We are asking all women who are attending this clinic, who are having the same 
surgical procedure as you are under spinal anaesthetic, to take part.  Every woman 
who agrees to take part in the study will receive either the one dose, or the other dose 
of local anaesthetic that is part of the spinal injection.  If you agree to take part in the 













sealed envelope, which will be opened immediately before your anaesthetic.  Only the 
doctor who is doing the spinal anaesthetic will know which dose was given. 
 
 
How long will I personally be involved? 
 
Almost all of the information that we need for our study will be collected on the day 
of your surgical procedure, both during the procedure and for a few hours 
immediately after your procedure until you are ready to go home.  During your next 
follow up clinic visit, we will ask you about any possible side effects of the spinal 
anaesthetic, which are very uncommon.   
 
 
What anaesthetic management will I receive? 
 
If it is safe to do so, you will have a spinal anaesthetic, which is our routine for this 
procedure.  The anaesthetic doctor doing your anaesthetic will inform you about the 
actual anaesthetic.  He/she will explain to you how the anaesthetic is performed.  
Then you will be able to give your consent for the spinal anaesthetic.  This is part of 
normal medical practice and will take place anyway, whether you take part in the 
study or not. 
 
What is specific to the study is that we are collecting information during the time that 
you are under the effects of the spinal anaesthetic.  For example, we will measure 
your blood pressure, assess how good your level of pain control is, the amount of 
weakness you have in your legs, as well as how long it takes for you to recover from 
the effects of the spinal anaesthetic. 
 
 
What will happen if I decide not to take part in the study? 
 
You do not have to take part in the study.  If you decide not to take part, you will still 
get the same quality of care for your specific illness, both now and in the future.  You 
will still get a spinal anaesthetic if safe to do so.  You may decide to stop being 















What are the risks to you? 
 
The risks to you are the same as for any spinal anaesthetic and will be explained to 
you by the doctor doing the anaesthetic.  Should you have any discomfort during the 
surgical procedure, the anaesthetic doctor will offer you additional medicine.  In the 
very unlikely event that you have severe discomfort, you may have to have a general 
anaesthetic for the procedure in addition to having the spinal anaesthetic. 
 
 
Are there benefits to you for being in this study? 
 
There are no extra benefits to you for being involved in this study.  The care and 
attention you will receive whilst having the surgical procedure are part of routine 
medical practice. There are no financial benefits to you for being involved in this 





The personal information we collect from those who take part in the study will only 
be shared among the doctors who are involved in the study.  The study may be 
published in a medical journal and the results of the group as a whole shared with 
those who read it.  However, there will be no way for the general public to know the 
identity of those who took part in the study.   These few doctors who will be 
responsible for looking at the results are the “principal investigators” mentioned at the 
start of this information document.  It is also important that the Human Research 
Ethics Committee (HREC) of the University of Cape Town is able to have access to 
the results of the study.  They do so in relation to their regulatory duties which seek to 
act in your favour.  Be assured that no blood samples will be taken from you during 



















I hereby confirm that the doctor who has signed below has informed me about the 
nature, conduct, benefits and risks of this clinical trial. I have also received, read and 
understood this written “PATIENT INFORMATION AND INFORMED 
CONSENT” form. I have had enough opportunity to ask questions and I agree to take 







________________________________                __________ 
   





_______________________________________  ___________ 





_________________________________________   _____________
   
Name and Signature of Witness/Interpreter   Date 


























Part B: STRUCTURED LITERATURE REVIEW 
 
a) Objectives of Literature Review 
 
The purpose of this literature review, conducted before drafting the research proposal, 
was to educate and hence guide myself regarding the rationale for and conduct of the 
study. My overall aim was to find the most suitable dose regimen for spinal 
anaesthesia for day-stay brachytherapy for carcinoma of the cervix at Groote Schuur 
Hospital. 
 
b) Literature search strategy 
 
The initial search was done during the second half of 2008 using ‘PubMed’, a 
recognized search portal for medical journal articles. Medical subject headings (key 
words) used were “low” and “dose” and “spinal” and “anaesthesia”. Together they 
found 514 results. Adding the search terms “ambulatory” or “day case” to the above 
four terms separately yielded a total of only 42 and 14 results respectively. To avoid 
missing important references on the subject, I manually filtered through all 514 initial 
results by reading their titles and occasionally the abstracts as well, choosing 66 
articles thought to be potentially relevant to the subject. After reading the abstracts of 
these 66 articles, it was only the 33 articles referenced below that were thought to be 
applicable to our study. 
 
I was most interested in studies comparing the various types and doses of local 
anaesthetics available for spinal anaesthesia, as well as the variety of drugs used as 
additives in spinal solutions. Literature relevant to design methodology was also 
viewed in order to give necessary guidance regarding the conduct of the study. 
 
Studies that were excluded were those involving children and those not exclusively 
related to spinal anaesthesia, i.e. either epidural or combined spinal-epidural 
anaesthesia. Those involving pregnant patients, for either labour analgesia or spinal 
anaesthesia for Caesarean section, were largely disregarded because the conclusions 
thereof cannot logically be applied to the non-pregnant patient due to the 













suitable were those describing selective, unilateral spinal anaesthesia, a technique not 
applicable to our study.  
 
c) Quality criteria  
 
Those articles found to be most useful were good reviews on the subject of low dose 
spinal anaesthesia and well-designed prospective, randomised controlled trials 
comparing different local anaesthetics, their doses and additives for spinal anaesthesia 
for day-stay (ambulatory) surgery. 
 
d) Summary and interpretation of literature (implications for research) 
 
Spinal Anaesthesia (SA) can be suitably performed for a variety of day-stay 
(ambulatory) surgical procedures. [1-2] The time taken for recovery to allow 
discharge home from hospital is an important consideration, as it impacts not only on 
patient satisfaction, but also on human and financial resource constraints within a 
hospital. As a reasonable alternative to general anaesthesia, spinal anaesthesia should 
provide reliable anaesthesia and there should be rapid recovery with few side effects. 
This necessitates the rational use of local anaesthetics and appropriate use of additives 
for spinal solutions, tailored specifically to the nature (site) and duration of the 
intended surgery. [1-3] It is therefore vital to understand the factors that influence the 
intrathecal spread of local anaesthetics, in order to choose the most appropriate drug 
combination and dose regimen for the required surgery. [2]   
 
Choice of local anaesthetic 
 
Many local anaesthetics have been successfully used for day case surgery, each with 
their respective advantages and disadvantages. Lidocaine was widely used for spinal 
anaesthesia from 1948 until the mid – 1990’s. However, in the mid – 1990’s serious 
concerns were raised regarding its safety for sub-arachnoid administration due to 
various case reports of transient neurological symptoms (TNS) and even permanent 
neurological injury on occasion. Although the short duration of action makes it rather 
suitable for ambulatory surgery, concerns regarding its safety have meant that 













Certainly, studies showed that there was a much higher incidence of transient 
radicular symptoms after use of lidocaine, when compared to bupivacaine, for spinal 
anaesthesia. It was found that this statistically significant difference was not 
dependent on the baricity of the lidocaine either and was a problem even at the lowest 
possible concentrations used in clinical practice i.e. it was a specific drug effect. [4-8] 
 
Recently there has been renewed interest in using the “older” local anaesthetics (first 
used intrathecally in the 1950-1970’s), for spinal anaesthesia in the day case setting. 
The short-acting drugs articaine and chloroprocaine, as well as prilocaine with its 
intermediate duration of action, have all been used successfully and are all thought to 
cause less TNS than lidocaine. [5-6] Mepivacaine has also been associated with TNS 
following intrathecal use. [9] 
 
Prilocaine may have significant advantages over bupivacaine for ambulatory surgery. 
In a recent study published in 2011 low dose prilocaine (20 mg) was compared to low 
dose plain bupivacaine (7.5 mg), both combined with fentanyl 20 ug, for spinal 
anaesthesia for ambulatory arthroscopic surgery of the knee. The prilocaine group had 
a shorter duration of motor block, faster regression of sensory block and less clinically 
significant decreases in arterial blood pressure, all of these outcomes reaching 
statistical significance. [10] 
 
Various studies have investigated the use of ropivacaine for spinal anaesthesia and its 
potential advantage over bupivacaine for ambulatory surgery in terms of the amount 
of motor blockade encountered. Some authors initially thought that ropivacaine had a 
similar analgesic efficacy and yet a lesser degree of motor block when compared to 
the same concentration of bupivacaine. [11] In a well-conducted study designed to 
evaluate the relative potency and dose-response characteristics of ropivacaine, it was 
shown to have about half the analgesic potency of bupivacaine and at equipotent 
doses a similar degree of motor block. [12] Ropivacaine holds no significant 
advantage over bupivacaine for spinal anaesthesia for day-stay surgery. [12-13]  
 
Levobupivacaine is a suitable alternative to bupivacaine when used for low dose 
spinal anaesthesia for day-stay surgery, being associated with less motor block as well 













The use of drugs at any given institution depends on various organisational and local 
traditional factors. At Groote Schuur Hospital the local anaesthetics lidocaine and 
bupivacaine are freely available. We favoured bupivacaine for spinal anaesthesia over 
lidocaine, due to the procedural requirement for at least an hour of anaesthesia, as 
well as the known better risk profile of bupivacaine in terms of transient neurological 
symptoms. 
 
Baricity of chosen local anaesthetic 
 
Hyperbaric bupivacaine was preferred to plain bupivacaine, due to its more consistent 
and reliable subarachnoid spread, as well as having a relatively shorter duration of 
complete motor blockade. [15-18] When considering the spread of bupivacaine in the 
sub-arachnoid space, the addition of dextrose to the local anaesthetic makes the 
solution more dense as well as more viscous, which leads to a more definite and 
consistently reliable spread (as compared to the dextrose-free solution) when the 
patient is in the supine position. [15]  
 
Knowledge of the fact that the spread of hyperbaric bupivacaine in the cerebro-spinal 
fluid (CSF) is affected by patient positioning during the first 20 – 30 minutes after 
injection (as the solution tends to “fall” under the influence of gravity) means that the 
clinician is able to use this to their advantage by intentional patient positioning 
immediately after injection of the solution. In our study, for example, by keeping the 
patient sitting for a duration of 2 minutes after the injection of hyperbaric bupivacaine 
into the sub-arachnoid space, the clinician will ensure that the bupivacaine will at first 
descend into and “bathe” the lower lumbar and sacral nerve roots. Thereafter, placing 
the patient supine and then almost immediately in the lithotomy position (for the 
remaining duration of the procedure), the hyperbaric bupivacaine will spread (in a 
more reliable and consistent manner than “plain” bupivacaine) under the influence of 
gravity, from the point of injection to include not only the sacral, but also the lumbar 
and lower thoracic nerve roots. 
 
A study examining the effect of baricity on spinal anaesthesia using bupivacaine 
showed that the hyperbaric solutions produced a greater cephalad spread and yet the 













beneficial effect of increasing the “height” (dermatomal level of anaesthesia) of the 
sensory block without increasing its duration. [16] Another study designed to 
investigate the effect of glucose concentration on the intrathecal spread of 0.5% 
bupivacaine confirmed these findings and showed that the average maximum extent 
(or height) of sensory block was significantly higher with 8% glucose as compared to 
either 0.83% or 0.33% glucose. [17] 
 
Furthermore, in a double-blind study of motor blockade in the lower limbs, comparing 
the same dose of either hyperbaric or glucose-free bupivacaine 0.5%, it was found 
that the glucose-free solution caused complete motor block of significantly longer 
duration. [18] This would be an unwanted effect in our study as it would supposedly 
lead to decreased patient satisfaction. 
 
It is for these reasons that  hyperbaric bupivacaine was considered a better choice than 
plain or dextrose-free bupivacaine (the latter in fact becomes hypobaric at body 
temperature, when injected intrathecally) for our study population undergoing this 
specific procedure. 
 
The minimum effective anaesthetic concentration (MEAC) of bupivacaine for spinal 
anesthesia has been calculated. MEAC is defined as the median effective 
concentration at which a spinal anaesthetic produces surgically equivalent anesthesia 
within 20 minutes of administration in 50% of human subjects. In healthy volunteers 
the MEAC of hyperbaric bupivacaine for spinal anaesthesia up to dermatomal level 
T12 using pin-prick sensation, was 0.43% (95% confidence interval 0.24-0.62) when 
10 mg was administered. [19] 
 
Additives to the local anaesthetic 
 
Many drugs have been investigated as additives to local anaesthetics for intrathecal 
use, with the aim of intensifying analgesia without causing any unwanted effects like 
prolonging recovery. This allows a lower dose of local anaesthetic to be used and 
hence hasten complete recovery from spinal anaesthesia, an advantage in ambulatory 













Although adding clonidine 15-30 ug to hyperbaric bupivacaine 5 mg for intrathecal 
use improved analgesic quality, it was also associated with an increase in duration for 
complete regression of motor block as well as time to spontaneous voiding. [20] 
Another study compared the effects of low dose clonidine and dexmedetomidine on 
bupivacaine-induced spinal anaesthesia. Dexmedetomidine 3 ug and clonidine 30 ug 
caused a similar increase in the duration of both sensory and motor block. [21] 
 
Adding magnesium sulphate 50 mg to intrathecal bupivacaine and fentanyl for spinal 
anaesthesia for ambulatory knee arthroscopy was not advantageous either because it 
also prolongs time to ambulation without significantly decreasing analgesic 
consumption in the first 24 hours after surgery. [22] 
 
Ketamine has also been successfully used as an additive to bupivacaine for spinal 
anaesthesia. In a study comparing bupivacaine 10 mg to bupivacaine 7.5 mg with S(+) 
ketamine 0.1 mg for spinal anaesthesia for prostate surgery in the elderly, this 
combination of S(+) ketamine and low dose bupivacaine resulted in a shorter onset 
time for both motor and sensory block, a shorter duration of action and less motor 
blockade. [23] In this regard the S(+) isomer of ketamine acts as a potent analgesic 
and has a similar clinical effect as the opiates. A benefit to using ketamine as an 
additive to local anaesthetics for spinal anaesthesia is that it has the ability to maintain 
cardiovascular stability relatively well. [24] 
 
The use of intrathecal opioids can enhance analgesia allowing for a lower dose of 
local anaesthetic to be used. Amongst the short-acting opiates that have been 
investigated for intrathecal use, fentanyl is perhaps the most widely studied and most 
commonly used clinically. A study looking at the value of adding fentanyl 25 ug to a 
low dose of bupivacaine (4 mg) for spinal anaesthesia for trans-urethral prostatectomy 
compared this group of patients to those receiving a conventional dose of plain 
bupivacaine 7.5 mg alone. The fentanyl-bupivacaine combination resulted in 
satisfactory analgesia as well as having the benefits of a lesser degree and duration of 
motor block, less hypotension and shivering. [25] 
 
Some clinicians believe that sufentanil is just as good, if not better than fentanyl in 













compared to each other, when combined with low dose bupivacaine (4 mg) for spinal 
anaesthesia for trans-urethral prostatectomy. Those who received sufentanil 5 ug had 
a higher peak level of sensory block and less requirement for perioperative analgesics 
than those who received fentanyl 25 ug, with no difference between the groups for the 
degree of motor block. [26] 
 
A study compared the use of intrathecal bupivacaine alone with bupivacaine 
combined with either sufentanil 10 ug or butorphanol 25 ug for spinal anaesthesia for 
endoscopic urology surgery. Both sufentanil and butorphanol increased the duration 
of sensory block without increasing the duration of motor block. The benefit of 
butorphanol over sufentanil was that it had less tendency to cause pruritus. [27] 
 
The synergistic effect of a small dose of intrathecal fentanyl with bupivacaine 
improves the quality of anaesthesia without the drug prolonging recovery from spinal 
anaesthesia. [3] This has allowed very small doses of bupivacaine to be used 
effectively for ambulatory surgery. Low dose hyperbaric bupivacaine (5 mg), when 
combined with fentanyl 25 ug for spinal anesthesia for endoscopic urological 
procedures, resulted in a shorter duration of sensory and motor block, with less use of 
ephedrine as vasopressor when compared to higher doses of hyperbaric bupivacaine. 
[28] 
 
In summary, a lower dose of bupivacaine combined with fentanyl, may provide 
adequate sensory blockade (and analgesia) but have the advantage of a shorter 
duration of action with less motor blockade. Although adding fentanyl to bupivacaine 
injected intrathecally has been shown to prolong the time taken for sensory block 
regression, this does not translate into a significantly longer time for the patient to 
start mobilizing and walk unaided, or the time taken to urinate, or the time taken to be 
eligible for discharge from the hospital. [29]  
 
The amount of fentanyl added is another factor to be considered, because the higher 
the dose the greater the risk of unwanted side effects. Doses of intrathecal fentanyl 
greater than 15 ug cause clinically significant pruritus. [30-31] Intrathecal opiates are 
also known to inhibit bladder function, which could delay the patient’s ability to void 













However, Ben-David et al. found that intrathecal opiates did not in fact delay the 
return of bladder function or the time to discharge. [29]  
 
When considering the evidence from the literature, 15 ug fentanyl was considered the 
optimal dose when used as an additive to hyperbaric bupivacaine for spinal 
anaesthesia in ambulatory surgery. Our study was undertaken to help establish the 
best dose of hyperbaric bupivacaine, when combined with intrathecal fentanyl 15 ug, 
for spinal anaesthesia for brachytherapy (immediate-proximity radiotherapy) for 
carcinoma of the cervix. There are no other studies investigating the use of low dose 
spinal anaesthesia in this group of patients and the results of our study will be useful 
in the generation of specific guidelines for spinal anaesthesia for this specific 
procedure.  
  
The primary outcome variable in our study was the time taken for complete recovery 
from spinal anaesthesia, i.e. for all of the discharge criteria to be fulfilled. In order to 
calculate an appropriate sample size for the patient groups to adequately power the 
study, we relied on clinical data previously collected on the same group of patients at 
Groote Schuur Hospital as well as the results of previous dose-response studies. From 
these we expected a mean duration to full recovery from spinal anaesthesia of 195 
(full range: 170-220) and 275 (full range: 250-300) minutes for our low dose 
(hyperbaric bupivacaine 5 mg + fentanyl 15 ug) and high dose (hyperbaric 
bupivacaine 9 mg + fentanyl 15 ug) groups respectively. [3,15-18,29] 
 
The dermatome level of the sensory block was measured using cold sensitivity to 
ethyl chloride spray. The sensory (dermatomal) level measured can vary greatly 
between clinicians unless a recognized, standardized method is used. In our study 
protocol we prescribed the method as follows: assessment started from above the level 
of sensory block achieved and the dermatome level at which the patient first noticed 

















To record the degree of motor block we used the modified Bromage scale as 
published in the literature: [18,33] 
 
0 = Full leg movement (full flexion of knees and ankles) 
1 = Inability to raise extended legs, just able to flex knees, full ankle flexion 
2 = Inability to flex knees, some flexion of ankles possible 
3 = No movement possible (unable to move legs or feet) 
 
e) Need for further research 
 
Further studies on SA for brachytherapy would help to establish the optimal dose 
regimen. In particular, a larger sample size would give a better indication of 
differences in quality of analgesia. In ideal circumstances without any resource or 
time constraints, an ED 50 / ED 95 dose-response study for hyperbaric bupivacaine 
(when combined with fentanyl 15 ug) for this specific procedure would possibly give 
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The purpose of this study was to help establish the most suitable dose of hyperbaric 
bupivacaine for spinal anaesthesia for day-stay brachytherapy for carcinoma of the 
cervix. The study was a prospective, randomised, double-blind trial. Forty patients 
were randomised to receive either 1 ml of hyperbaric bupivacaine 0.5% (5 mg) plus 
15 µg fentanyl (Low Dose, n=20), or 1.8 ml of hyperbaric bupivacaine 0.5% (9 mg) 
plus 15 µg fentanyl (High Dose, n=20), via the L3/4 interspace. The time to achieve 
hospital discharge criteria was significantly shorter in the Low Dose (LD) group 
(mean time of 235 [206-264] minutes) versus the High Dose (HD) group (mean time 
of 280 [263-297] minutes) (p < 0.01). Patients in the LD group were also eligible for 
discharge from the recovery area in a shorter time (p < 0.01). Although there was 
significantly less motor block in the LD group (p < 0.001), patient satisfaction 
regarding motor block was the same in the two groups (p = 0.96). There was a trend 
towards more inadequate (unsatisfactory) spinal blocks in the low dose group  




Spinal anaesthesia (SA) can be suitably performed for a variety of day-stay 













discharge home from hospital is an important consideration, as it impacts not only on 
patient satisfaction, but also on human and financial resource constraints within a 
hospital.  The dose and type of local anaesthetic used needs to be specifically tailored 
to the nature (site) and duration of the intended surgery. [1-2]   
 
This study was undertaken to help establish the best dose of hyperbaric bupivacaine, 
when combined with intrathecal fentanyl, for spinal anaesthesia for brachytherapy 
(immediate-proximity radiotherapy) for carcinoma of the cervix. These day-stay 
surgical patients undergo insertion of an intra-cervical (‘Smit sleeve’) stent which is 8 
mm in diameter, the stent facilitating subsequent introduction of an applicator 
necessary to perform brachytherapy.  The procedure also involves probing (sounding) 
the fundus of the uterus which requires a spinal block up to- and including the T10 
dermatome level.   
 
During 2008 – 2009 data were retrospectively analysed after varying clinical practice 
by several anaesthetists performing spinal anaesthesia for brachytherapy at Groote 
Schuur Hospital (unpublished). Sixteen patients received doses of between 0.5-1.8 ml 
of hyperbaric bupivacaine 0.5%, combined with either 15 or 20 µg of fentanyl. None 
of the patients required conversion to general anaesthesia and none required IV 
supplementary analgesia. Time taken for regression of sensory block to dermatome 
level S2 in this sample patient population varied between 190 – 200 minutes for a 
dose of 1 ml of hyperbaric bupivacaine 0.5% (5 mg) and 240 – 250 minutes for 
patients receiving a dose of 1.8 ml of hyperbaric bupivacaine 0.5% (9 mg). 
 
It was therefore decided to conduct a prospective study comparing what may be 
considered a relatively standard or conventional dose of heavy bupivacaine, with a 
lower dose, both combined with fentanyl 15 µg, for spinal anaesthesia. The aim was 
to provide adequate anaesthesia using the lower dose, as well as allowing for a shorter 
time to complete recovery.  The study findings could then be used to contribute to a 



















This prospective, randomized study was approved by the Human Research Ethics 
Committee (HREC) of the University of Cape Town. Patients attending the 
radiotherapy clinic scheduled for brachytherapy for carcinoma of the cervix were 
included in the enrolment process, the only exclusion criteria being either a contra-
indication to spinal anaesthesia or unwillingness on the part of the patient to take part 
in the study. Written informed consent for the study was obtained in the patient’s first 
language, at least 12 hours before the procedure, and a copy given to the patient for 
their reference.  
 
A literature review suggested similar times for eligibility for hospital discharge as in 
the Groote Schuur pilot data, namely a mean of 195 (full range: 170-220) minutes for 
the low dose group and 275 (full range: 250-300) minutes for the high dose 
group.[2,4-7] Using this information, power analysis using the statistical package 
Stata (Stata/IC 12.1, StataCorp, LP, 4905 Lakeway Drive, College Station, TX 77845, 
USA) calculated that 18 patients would be needed in each group at an alpha level of 
0.05 and a beta value of 0.90 to detect this difference. We decided to enrol 20 patients 
into each group to minimise the possibility of a beta-error in the study. 
 
Patients were randomised by a sealed envelope technique and allocated to either the 
Low Dose (LD) or High Dose (HD) group in the following manner: 20 LD labels and 
20 HD labels were each placed into 40 separate envelopes which were then sealed, 
shuffled extensively and then labelled as “patient number 1” through to “patient 
number 40”. During the study these envelopes were opened in order from patient 
number 1 – 40 by the anaesthetists performing each spinal anaesthetic, but then put 
back into the same envelope and closed again. The group allocation of each envelope 
was only made known to the data collector and primary investigator after recruitment 
was complete and data ready to be analysed.  
 
Patients received a subarachnoid dose of either 1 ml of hyperbaric bupivacaine 0.5% 
(5 mg) plus 15 µg fentanyl (Group Low Dose [LD], n=20), or 1.8 ml hyperbaric 













Prior to performing spinal anaesthesia, an 18 gauge cannula was inserted for 
intravenous (IV) access and standard monitoring (pulse oximeter, non-invasive blood 
pressure and ECG) applied. IV midazolam 0.025 mg.kg
-1
 (maximum of 2 mg) was 
given to all patients younger than 65 years of age (n=38, 19 from each group). 
Baseline systolic blood pressure was calculated as the mean of two systolic blood 
pressures measured at rest during the five minutes prior to spinal anaesthesia.  
 
Spinal anaesthesia was administered using an aseptic technique with the patient in the 
sitting position. A 25 gauge Whitacre spinal needle was introduced via the L3/4 
interspace and once free flow of clear cerebro-spinal fluid (CSF) was demonstrated, 
the solution was injected over 10-15 seconds. The patient remained sitting for two 
minutes after completion of the injection and was then re-positioned in the lithotomy 
position for surgery.  
 
A different anaesthetist who was blinded to the treatment group of the patient was 
responsible for patient monitoring and clinical data collection for the study. 
Therefore, both the patient and the attending anaesthetist for the duration of the study 
were blinded (double-blinded study). Lactated Ringer’s solution 500 – 1000 ml was 
administered as a co-load.  Blood pressure was measured every three minutes after 
induction of anaesthesia.  A decrease in systolic blood pressure to less than 80% of 
the mean baseline value was treated with 5 mg ephedrine IV and the dose repeated as 
necessary.  
 
The dermatomal level of the sensory block was measured using cold sensitivity to 
ethyl chloride spray. The level of sensory block was assessed every five minutes until 
the height of the block had remained constant for three consecutive readings, i.e. until 
the sensory block was fully established. Thereafter the level was assessed every 10 
minutes until there had been a regression in sensory block of at least two dermatomes, 
thereafter every 15 minutes until all of the hospital discharge criteria had been met. 
Time taken to eligibility for discharge from the theatre recovery area (sensory level 
T10 or lower, together with cardiovascular stability) was noted. 
 
Planned management in the case of failed or inadequate spinal anaesthesia was as 













Once there was evidence that a sensory block to a particular dermatomal level had 
been achieved, the patient was asked to grade their quality of anaesthesia (sensation) 
and their description at the start of the procedure was categorized into one of four 
groups (appendix A). If the patient fell into groups 1-3, the quality of pain control was 
deemed adequate and the surgical procedure continued without giving any 
supplemental analgesia or converting to a general anaesthetic. If, however, the patient 
was experiencing discomfort or pain and either requested or agreed to additional pain 
relief upon being offered it, or was in obvious need of additional analgesia, the patient 
was allocated to group 4 and the spinal anaesthetic regarded as inadequate for the 
planned surgical procedure. The attending anaesthetist then explained to the patient 
that general anaesthesia would be required for the surgery. 
 
The primary outcome variable was the time taken to achieve the clinical criteria for 
discharge from the hospital, i.e. all of the following to be achieved: 
- Regression of sensory block to the S2 dermatome 
- Ability to walk unaided 
- Ability to void urine 
 
Secondary outcomes included the following information and comparisons: 
- Time to eligibility for discharge from theatre recovery area (sensory level 
at or below the T10 dermatome, with cardiovascular stability) 
- Quality of analgesia: sensation felt by the patient during the procedure 
(appendix A) 
- Degree of motor blockade at the time of peak sensory blockade  
(appendix B) 
- Patient satisfaction, rated on a visual analogue scale (VAS) from 0 – 10, 
regarding both the quality of anaesthesia and degree of motor block 
experienced (appendix C) 
- The peak sensory dermatomal level and the time taken to reach this level 
- Side effects  
(nausea and/or vomiting, pruritus, light-headedness or dizziness) 














At the next clinic visit patients were specifically asked if they had had any pain not 
related to the operative site, but specifically in the buttocks, thighs or lower limbs 
(transient neurological symptoms) or those of post-dural puncture headache. Patients 
were encouraged to report these or any other symptoms experienced in the interim to 
the radiotherapist or the anaesthetist, whose contact telephone numbers were given. 
For statistical analysis, the Shapiro-Wilk test was used to establish whether data was 
normally distributed. For between-group comparisons of normally distributed 
numerical data, a two-sample Student’s T-test was used. This was the case for the 
primary outcome variable of the study. For non-normally distributed numerical data, 
the Wilcoxon rank sum (Mann-Whitney U) test was used. For categorical data the 
Fisher’s exact test was employed for between-group comparisons, since there were 
less than five observations in multiple categories. All statistical analyses were 
performed using the statistical package Stata (Stata/IC 12.1, StataCorp, LP, 4905 




Forty one patients were assessed for inclusion in the study, since one patient had to be 
excluded due to a contra-indication to spinal anaesthesia (idiopathic 
thrombocytopenic purpura, with a platelet count of 74x10
9
/L). Forty patients were 
randomised to either the LD (n=20) or the HD (n=20) group. There were no 
significant between-group differences in demographic data (Table I). The median 
duration (interquartile range [IQR]) for the surgical procedure for the 40 patients, 
measured from the time of intrathecal injection of the spinal solution to the transfer of 
the patient to the recovery area, was 60 (52-70) minutes. 
 
The data relating to discharge ability from the hospital was found to be normally 
distributed (Shapiro-Wilk test value 0.56 [p> 0.05]). Between-group comparisons of 
eligibility criteria for discharge ability from recovery room to the ward, and from the 
hospital, are shown in Table II. The LD group demonstrated statistically significantly 
shorter discharge ability times from recovery room and the hospital, overall and as 
regards each individual criterion for hospital discharge ability. In one patient in the 
LD group, there was no spinal block established after injection. This patient was thus 













In terms of quality of anaesthesia, five of the 40 patients were assessed as having 
inadequate spinal anaesthesia. These patients had their quality of analgesia graded as 
a “4” (Appendix A) and general anaesthesia was appropriately administered, 
according to the protocol. Four of these patients were from the LD group and one 
from the HD group. Comparing the two groups specifically for this category of 
“inadequate” spinal anaesthesia, the Fisher’s exact test was used. There was a trend 
towards more failures in the LD group. (Table III). Comparing the two groups for 
quality of analgesia within their original categories of 1-4, the results were also not 
statistically significant (Table IV). 
 
The degree of motor block was assessed using the modified Bromage scale – see 
appendix B. [8-9] The LD group had significantly less motor block than the HD group 
(Table V). There was no statistically significant difference between the two groups in 
terms of patient satisfaction (Table VI). Amongst the other results, the LD group had 
a lower peak sensory dermatome level (Table VII).  
 
There were no symptoms of nausea, vomiting or pruritus in any of the patients. On 
direct questioning only two of the 40 patients admitted experiencing dizziness, one 
patient from each group. None of the patients had any symptoms consistent with 
transient neurological symptoms on follow up. One patient had symptoms suggestive 
of a post-dural puncture headache which improved with conservative management 




The purpose of our study was to compare a conventional dose of hyperbaric 
bupivacaine for spinal anaesthesia for day stay brachytherapy for carcinoma of the 
cervix, with a lower dose, with a view to shortening the time to full recovery without 
compromising quality of analgesia during the procedure. The study showed 
statistically significantly shorter time to readiness for hospital discharge in the LD 
group, with less motor block. Both groups had minimal side effects. There was a trend 














We favoured bupivacaine for spinal anaesthesia over lidocaine, due to the procedural 
requirement for at least an hour of anaesthesia, as well as the known better risk profile 
of bupivacaine in terms of transient neurological symptoms. [1,10-12] Hyperbaric 
bupivacaine was preferred to isobaric bupivacaine, due to its more consistent and 
reliable subarachnoid spread, as well as having a relatively shorter duration of 
complete motor blockade. [6,8,13] The synergistic effect of a small dose of intrathecal 
fentanyl with bupivacaine improves the quality of anaesthesia, without the drug 
prolonging recovery from spinal anaesthesia. [5] This allows for a smaller total dose 
of bupivacaine to be used, potentially shortening the time to complete recovery. 
 
In choosing our dose regimen of hyperbaric bupivacaine for the two groups, we were 
guided by clinical information collected before the study began, as well as a review of 
the published literature on the subject. In a dose-response study of hyperbaric 
bupivacaine for spinal anaesthesia in volunteers, bupivacaine 3.75 mg and 7.5 mg 
achieved a median peak dermatomal block to pinprick of T9 (IQR=5 dermatomes) 
and T7 (IQR=5 dermatomes) respectively. [2]  
 
In another dose-response study using different doses, volumes and concentrations of 
glucose-free bupivacaine for spinal anaesthesia in patients undergoing trans-urethral 
surgery, bupivacaine 10 mg achieved a peak sensory level of T5-T8. [4] It seems that 
the intrathecal spread of a local anaesthetic is primarily determined by the dose given 
rather than depending on its volume or concentration. [4,14]   
 
Our study analysed the clinical response to two different doses of hyperbaric 
bupivacaine, when combined with fentanyl 15 µg, for spinal anaesthesia in the 
ambulatory setting. It must be remembered, however, that our conclusions apply to a 
specific surgical procedure in a particular patient population, and cannot be loosely 
extrapolated to other groups of patients. 
 
An analysis of the primary outcome variable of our study, showed that patients in the 
LD group benefitted by being eligible for home discharge sooner than those in the HD 
group. Patients in the LD group were also eligible for discharge from the recovery 
area in a shorter time. Although there was significantly less motor block in the LD 













The trend towards more patients with inadequate spinal anaesthesia in the LD group 
was a concern. In an adequately powered study examining quality of analgesia, this 
may have achieved statistical significance. Power analysis using the statistical 
package Stata (Stata/IC 12.1, StataCorp, LP, 4905 Lakeway Drive, College Station, 
TX 77845, USA) calculated that for an alpha level of 0.05 and a beta value of 0.90 we 
would need 114 patients in each group to prove that the LD provided unsatisfactory 
spinal anaesthesia compared to the HD. However, it was not possible to conduct such 
a large study as we were limited by human resources and time constraints. 
 
Interestingly, the trend towards more inadequate spinal anaesthesia in the LD group 
was despite an acceptable median (IQR) peak sensory level, using ethyl chloride cold 
spray, of T8 (8-10) for the required surgery. This suggests that the quality of surgical 
anaesthesia for any given procedure cannot be predicted entirely by the dermatomal 
spread of local anaesthetic (or peak sensory level achieved) as assessed by cold 
sensitivity. 
 
The strength of this study is that prior to this, there have been no published 
prospective, randomised, double-blinded, controlled trials in this specific group of 
patients undergoing this specific procedure. Previously published data investigating 
the use of low dose spinal anaesthesia in patients undergoing trans-urethral resection 
of the prostate (TURP), for example, cannot reliably be extrapolated to our group of 
patients. The procedure our patients had is different and the physiology related to their 
underlying malignancy (of the cervix) may affect the pharmacokinetic and/or 
pharmacodynamics profile of the intrathecal solution. 
 
Our study suggests that a dose closer to- or equivalent to that of the HD group may be 
preferable, to ensure consistent and reliable spinal anaesthesia in this patient 
population.  This may be more important than a statistically significantly shorter 
hospital discharge time and less motor block. Similar conclusions were drawn from a 
recent meta-analysis examining the use of low-dose spinal anaesthesia for caesarean 
delivery, which cautioned against the use of low dose bupivacaine for single shot 














A considerable weakness of our study, related to the human resource and time 
constraints we faced, was that we only compared two different doses of hyperbaric 
bupivacaine. Ideally we would have liked to conduct a dose-response study for 
hyperbaric bupivacaine, when combined with intrathecal fentanyl 15 ug, to determine 
the ED 50 and ED 95 for our specific group of patients. Alternatively, an ED 50 dose-
finding study using the minimum local anaesthetic concentration (MLAC) for 
hyperbaric bupivacaine would have been extremely valuable. Further studies 
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Appendix A:  Quality of anaesthesia (sensory block) 
 
1- Complete absence of any sensation 
2- Sensation of motion only 
3- Mild discomfort, but declining offer for additional analgesia 
4- Patient requests additional analgesia / in obvious need of additional analgesia 
 
Appendix B:  Modified Bromage scale [8-9] 
 
0 = Full leg movement (full flexion of knees and ankles). 
1 = Inability to raise extended legs, just able to flex knees, full ankle flexion. 
2 = Inability to flex knees, some flexion of ankles possible. 













Appendix C:  Patient questionnaire 
(Mark the spot on the line below that best describes your experience) 
 
1) How satisfied are you, overall, with the spinal anaesthetic you received for 
your surgical procedure?  
 
______________________________________________________________ 
0 1 2 3 4 5 6 7 8 9 10 
Completely   A little   Reasonably      Completely 
Dissatisfied   dissatisfied  satisfied          Satisfied 
 
If you marked a value below 5, please say why: _________________________ 
 
2) How satisfied are you with the amount of pain/discomfort you felt during the 
surgical procedure?  
 
______________________________________________________________ 
0 1 2 3 4 5 6 7 8 9 10 
Completely   A little   Reasonably      Completely 
Dissatisfied   dissatisfied  satisfied          Satisfied 
 
If you marked a value below 5, please say why: _________________________ 
 
3) How satisfied are you with the amount of weakness in your legs experienced 
during and after the procedure? 
 
______________________________________________________________ 
0 1 2 3 4 5 6 7 8 9 10 
Completely   A little   Reasonably      Completely 
Dissatisfied   dissatisfied  satisfied          Satisfied 
 


















1. Kopp SL, Horlocker TT. Regional anaesthesia in day-stay and short-stay 
surgery. Anaesthesia 2010; 65 (Suppl. 1): 84–96. 
 
2. Liu SS, Ware PD, Allen HW, Neal JM, Pollock JE. Dose-response 
characteristics of spinal bupivacaine in volunteers. Clinical implications for 
ambulatory anesthesia. Anesthesiology 1996; 85: 729-736. 
 
3. Yentis, SM. Height of confusion: assessing regional blocks before caesarean 
section. International Journal of Obstetric Anesthesia 2006; 15: 2–6. 
 
4. Sheskey MC, Rocco AG, Bizzarri-Schmid M, Francis DM, Edstrom H, 
Covino BG. A dose-response study of bupivacaine for spinal anesthesia. 
Anesthesia & Analgesia 1983; 62: 931-935. 
 
5. Ben David B, Solomon E, Levin H, Admoni H, Goldik Z. Intrathecal fentanyl 
with small-dose dilute bupivacaine: better anesthesia without prolonging 
recovery. Anesthesia & Analgesia 1997; 85: 560-565. 
 
6.   Chambers WA, Edstrom HH, Scott DB. Effect of baricity on spinal 
anaesthesia with bupivacaine. British Journal of Anaesthesia 1981; 53: 279-
282. 
7. Hocking G, Wildsmith JA. Intrathecal drug spread. British Journal of 
Anaesthesia 2004; 93: 568-578. 
8. Axelsson KH, Widman GB, Sundberg AE, Hallgren S. A double-blind study 
of motor blockade in the lower limbs. Studies during spinal anaesthesia with 
hyperbaric and glucose-free 0.5% bupivacaine. British Journal of Anaesthesia 














9. Fettes PDW, Hocking G, Peterson MK, Luck JF, Wildsmith JAW. 
Comparison of plain and hyperbaric solutions of ropivacaine for spinal 
anaesthesia. British Journal of Anaesthesia 2005; 94 (1): 107-111. 
 
10. Schneider M, Ettlin T, Kaufmann M, et al. Transient 
neurologic toxicity after hyperbaric subarachnoid anesthesia 
with 5% lidocaine. Anesthesia & Analgesia 1993; 76: 1154–1157. 
 
11. Rigler ML, Drasner K, Krejcie TC, et al. Cauda equina 
syndrome after continuous spinal anesthesia.  Anesthesia & 
Analgesia 1991; 72: 275–281. 
 
12. Carpenter RL. Hyperbaric lidocaine spinal anesthesia: do we need an 
alternative? Anesthesia & Analgesia 1995; 81: 1125-8. 
 
13. Bannister J, McClure JH, Wildsmith JA. Effect of glucose concentration on 
the intrathecal spread of 0.5% bupivacaine. British Journal of Anaesthesia 
1990; 64: 232-4. 
 
14. Kuusniemi KS, Pihlajama¨ki KK, Pitka¨nen MT, Korkeila JE. Low-dose 
bupivacaine: a comparison of hypobaric and near isobaric solutions for 
arthroscopic surgery of the knee. Anaesthesia 1999; 54: 540–545. 
 
15. Arzola C, Wieczorek PM. Efficacy of low-dose bupivacaine in spinal 
anaesthesia for Caesarean delivery: systematic review and meta-analysis. 





















Table I:  Patient characteristics – no difference between the 2 groups 
 
    Low Dose    High Dose  p-value 
 
Mean Age (SD) in years:  49.9 (45.7-54.1) 51.55 (46.95-56.15) 0.58* 
Mean BMI (kg.m-2):  27.5   26.9   0.84** 
ASA rating:   2, 3 (n=11, 9)  2, 3 (n=15, 5)  0.19*** 
 
* Two-sided Student’s T-test  
** Two-sample Wilcoxon rank-sum (Mann-Whitney U) test 




































Table II:  Primary outcome variable (minutes) –  
Shorter mean time (SD) to discharge home and from recovery area 
in the low dose group  
 
    Low Dose  High Dose  p -value 
Discharge recovery (n=40): 72 (64-81)  90 (82-97)  < 0.01* 
Hospital discharge (n=40): 235 (206-264)  280 (263-297)  < 0.01* 
Hospital discharge (n=39): 241 (214-268)  280 (263-297)     0.01* 
Time to walk (n=39):  219 (193-246)  268 (251-285)  < 0.01* 
Time to void (n=39):  235 (208-263)  271 (255-287)     0.02* 
Regression to S2 (n=39): 233 (208-258)  278 (256-301)  < 0.01* 
 


































Table III:  Number of adequate versus inadequate spinal anaesthetics - 
  actual number of patients (percentages) in each category 
 
 
    Low Dose  High Dose 
 
Adequate (category 1-3): 16  (80%)  19  (95%) 
Inadequate (category 4): 4 (20%)  1 (5%) 
 





































Table IV: Quality of anaesthesia (sensory block) – 
  actual number of patients (percentages) in each category 
 
    Low Dose  High Dose 
 
Category 1:   5 (25%)  12 (60%) 
Category 2:   8 (40%)  5 (25%) 
Category 3:   3 (15%)  2 (10%) 
Category 4:   4 (20%)  1 (5%) 
 




































Table V:  Grouping of patients according to the modified Bromage scale - 
  actual number of patients (percentages) in each category 
 
Score   Low Dose  High Dose  
0:   15 (75%)  3 (15%) 
1:   4 (20%)  3 (15%) 
2:   0 (0%)  4 (20%) 
3:   1 (5%)  10 (50%) 
 





































Table VI:  Patient satisfaction –  
median scores (IQR) are no different between groups 
 
  Low Dose    High Dose    p-value 
Q 1:  10 (IQR 7.5-10)  10 (IQR 10-10)  0.26* 
Q 2:  10 (IQR 5.5-10)  10 (IQR 10-10)  0.20* 
Q 3:  10 (IQR 8-10)   10 (IQR 9-10)   0.96* 
 






































Table VII:  Other measured variables (secondary outcomes) –  
higher peak sensory level achieved with the high dose 
 
     Low Dose High Dose p-value 
     (n=19)  (n=20) 
 
Median peak sensory level:   8 (IQR 8-10) 8 (IQR 6-8) < 0.01* 
Mean time to reach peak:   20 (15-20) 15 (15-20)    0.14* 
Use (need) of ephedrine  1 (5%)  3 (15%)    0.30** 
 
*Wilcoxon rank-sum (Mann-Whitney U) test 
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The Consort Statement (2010) Flow Diagram 
(Flow diagram of the progress through the phases of a parallel randomised trial of two groups (that is, 





Process of enrolment 
Assessed for eligibility:  n = 41 
Excluded:    n = 1: contra-indication to spinal anaesthesia 
Randomised:   n = 40 
 
Group allocation   
n = 20 in each group 
 
None were lost to follow-up or had their intervention discontinued 
 

















Patient Information and Informed Consent – Xhosa version 
 
 
Study Title: Spinal anaesthesia for brachytherapy for carcinoma of the cervix: a 
comparison of two dose regimens of hyperbaric bupivacaine 
 
Principal Investigators:  N Haus, RA Dyer (Contact No. 021 404 5001/3) 
UCT Human Research Ethics Committee (HREC) Ref no: 421/2010 
 
Patient Folder no:      
 (Place hospital sticker here) 
 
 





Uyamenywa ukuthabatha inxaxheba koluphando. Phambi kokuba ugqibe ukuba 
uyafuna na ukuthatha inxaxheba umelwe kukwazi ukuba oluphando lungantoni na. 
Emva kokuba ufunde eliphepha lengcaciso, wachazelwe ngokupheleleyo ngophando, 
ukuba unemibuzo okanye okunye onqwenela ukukuqonda, nceda ubuze ugqirha 




Lwenzelwa ntoni oluphando? 
 
Sigqibe ekubeni sithelekise imilinganiselo emibini yeyeza elihlatywa emqolo 
ukwenzela ukubulala intlungu(ukudonywa) ngexesha lonyango. Lendlela 
yokudonywa yenziwa ngokuhlatywa iyeza (“Bupivacaine”) emqolo. Sifuna ukuqonda 
ukuba umlinganiselo othile wokubulawa kwentlungu ungcono na kunomnye  
umlinganiselo weyeza lokubulala iintlungu. 
 
 
Kutheni ucelwa uthabathe inxaxheba kuphando? 
 
Sicela bonke abantu abahamba kulekliniki, abaze kunyangwa umhlaza wesibeleko 
ukuba bathabathe inxaxheba koluphando. Wonke umntu ovumayo ukuthabatha 
inxaxheba kolu phando ufumana umlinganiselo oqingqiweyo weyeza elihlatywa 
emqolo. Ukuba uyavuma ukuthabatha inxaxheba kolu phando, umlinganiselo 
ozakuwufumana uxhomekeke ekubeni kufunyanwa iyeza elingakanani emvulophini 

















Ndizakubandakanyeka ixesha elingakanani koluphando? 
 
Zonke inkcukatha esizidingayo ngophando, ziqokelelwa ngemini yonyango, ngexesha 
lokunyangwa kwakho nangeyure ezimbalwa emva kokusetyenzwa kwakho, ude ube 
ulungele ukugoduka. Xa ubuya usiza ekliniki, siza kubuza indlela oziva ngayo 




Ndizakufumana luphi uhlobo lokubulawa kwentlungu (ukudonywa)? 
 
Ukuba akukho bungozi bulindelekileyo, uzakudonywa ngokuhlatywa emqolo, into 
eluhlobo oluqhelekileyo lokubulawa kwentlungu kolunyango ulufumanayo. Ugqirha 
ozakukudoma uzakucacisela kabanzi ngendlela yokubulawa kwentlungu azakuyi-
sebenzisa. Uzakucacisela indlela azakukudoma ngayo. Emva koko, wena 
uzakunikezela ngemvume yokunikwa iyeza ngokuhlatywa inaliti emqolo. Le naliti 
ihlatywa emqolo yindlela eqhelekileyo yokubulawa kwentlungu kubantu abazele 
oluhlobo lonyango. Uzakuhlatywa emqolo nokuba awuthabathi nxaxheba kuphando. 
Into ejamelene ngqo nophando kukuqokelelwa kwenkcukhaca ngexesha umzimba 
wakho usadonyiwe ngenaliti ehlatywe emqolo. Umzekelo, sizakuthabatha iBlood 
Pressure yakho, sijonge nokuba iintlungu onazo zingakanani na, sijonge nokutyhafa 
kwemilenze ukuba kukangakanani na, nokuba kuthabatha ixesha elingakanani 
ukuphela kobundindisholo okubangelwe liyeza elihlatywe emqolo. 
 
 
Kuzakuthini ukuba andivumi ukuthabatha inxaxheba koluphando? 
 
Awunyanzelekanga ukuthabatha inxaxheba koluphando. Ukuba awufuni ukuthabatha 
inxaxheba koluphando, uzakuqhuba ufumane uhoyo olufanelekileyo kwisigulo onaso, 
na kwixa elizayo. Uzakubulawa intlungu ngokuhlatywa emqolo ukuba kukulungele 













Zeziphi izinto ezinokuba yingxaki kuwe ngokuthabatha inxaxheba koluphando? 
 
Ingxaki kuwe zifana nengxaki ezibakhona xa umntu ebulewe intlungu ngokuhlatywa 
iyeza emqolo. Ugqirha obulala intlungu uzakucacisela ngazo zonke iingxaki 
ezinokuvela. Ukuba kunokwenzeka uvakalelwe ziintlungu ngexesha lonyango, 
ugqirha obulala iintlungu unakho ukunika amayeza awongeziweyo ukuphelisa 
iintlungu. Ukuba kunokwenzeka okungaqhelekanga, okufana nokuqaqanjelwa 
kakhulu ngexesha lonyango, ugqirha obulala iintlungu uyakwazi ukukulalisa wonke 
ngaphezu kokuba uzakube ufumene iyeza elihlatywa emqolo elenza ndindisholo 
amazantsi omzimba kuphela. 
 
 
Kukhona okuzuzayo ngokuthabatha inxaxheba koluphando? 
 
Akukho nzuzo engaphezulu oyifumanayo ngokuthabatha inxaxheba koluphando. 
Uhoyo nenkathalo oyifumanayo ngexesha ufumana unyango, ziyinxalenye yohoyo 
obufanele ukulufumana esibhedlele. Akukho mali nantlawulo uzakuyifumana 





Iinkcukacha zakho ezifihlakeleyo, eziqokelelwe kwabo bathabatha inxaxheba 
kuphando zaziwa ngoogqirha ababandakanyeka kuphando kuphela. Iziphumo 
zophando zingabhalwa kwiincwadi zogqirha, zixoxwe zaziwe ngoogqirha abafunda 
ezoncwadi kuphela. Akukho ndlela yokuba abanye abantu ngokubanzi bangayazi 
ukuba ngobani abathabathe inxaxheba koluphando. Oogqirha abambalwa abazakuzazi 
iziphumo ngabo babandakanyekayo koluphando kuphela. Kubalulekile ukuba 
icandelo lezobuntloli neengcali zeyunivesi yase Kapa zikwazi ukuzifumana iziphumo 
zoluphando. Bazijonga eziziphumo ukwenzela ukukhusela wena nje 
ngomguli.Baqinisekisa ukuba konke okenziwayo akukonzakalisi ngokwasempilweni. 

















Ndiyaqinisekisa ukuba uGqirha obhalwe apha ngezantsi undicacisele ngentlobo 
yokubulawa kwentlungu nendlela oluzakuqhutywa ngayo oluphando, nazo zonke 
iinkcukaca zophando. Ndiyifundile ndayiqonda yonke imininingwane ebhalwe 
kweliphepha lokunikezela ngemvume. Ndifumene ithuba elaneleyo lokubuza 








________________________________                _____________  
    
Igama notyikityo lomntu othabatha inxaxheba kuphando       Umhla (Date) 




_______________________________________  ____________ 
Igama notyikityo lomntu othabatha imvume    Umhla (Date) 
(Name and Signature of Person obtaining Consent) 
 
 
_________________________________________   _____________
   
Igama notyikityo lomntu olingqina (Xa kusetyenziswe itoliki)  Umhla (Date) 


























Patient Information and Informed Consent (Afrikaans version) 
 
 
Study Title: Spinal anaesthesia for brachytherapy for carcinoma of 
the cervix: a comparison of two dose regimens of 
hyperbaric bupivacaine 
 
Principal Investigators:  N Haus, RA Dyer (Contact no. 021 404 5001/3) 
UCT Human Research Ethics Committee (HREC) Ref no: 421/2010 
 
Patient Folder no:      
 (Place hospital sticker here) 
 
 





U word uitgenooi om deel te neem aan hierdie studie. Voordat u besluit of u hieraan 
gaan deelneem, moet u ten volle verstaan wat dit behels. Nadat u hierdie inligting 
gelees en dit aan u verduidelik is, voel vry om enige vrae wat u het te deel met die 
dokter wat hierdie inligtingstuk met u deurgaan, of met die navorsers hierbo genoem. 
 
 
Waarom word hierdie studie gedoen? 
 
Ons het besluit om twee verskillende doserings van lokale verdowing, genaamd 
Bupivakaien, met mekaar te vergelyk. Dit is wat gebruik word wanneer die dokter die 
spinale narkose op jou doen. Ons wil vasstel of die een dosering beter is as die ander 




Waarom word u gevra om hieraan deel te neem? 
 
Ons vra al die dames wat hierdie kliniek besoek en dieselfde prosedure as u 
ondergaan, om deel te neem. Elke dame wat instem om aan hierdie studie deel te 
neem sal dan of die een of die ander dosering van lokale verdowing waarmee die 
spinale narkose gedoen gaan word, ontvang. Indien u instem om deel te neem, sal die 
dosering wat u gaan ontvang lukraak gekies word op grond van wat in ‘n verseelde 
koevert  verskyn. Die koevert word oopgemaak direk voordat u spinaal gedoen word. 



















Hoe lank sal ek persoonlik hierby betrokke wees? 
 
Feitlik al die inligting wat ons benodig vir ons studie sal gekollekteer word op die dag 
van u prosedure, beide tydens en vir ‘n paar ure na die prosedure totdat u gereed is om 
huis toe te gaan. Tydens u volgende kliniek besoek sal u gevra word oor enige 
moontlike newe effekte wat u ondervind het. Newe effekte is baie ongewoon. 
 
 
Watter tipe narkose sal ek ontvang? 
 
Indien daar geen teen-indikasies is nie sal u ‘n spinale narkose ontvang- wat die 
roetiene is vir hierdie prosedure. Die narkotiseur wat die spinaal gaan doen sal u 
volledig daaromtrent inlig. Hy/sy sal aan u verduidelik hoe die prosedure uitgevoer 
gaan word. Daarna sal u kan toestemming gee vir die uitvoer van die spinale narkose. 
Hierdie toestemming moet gegee word of u deelneem in die studie of  nie- dis deel 
van normale narkose praktyk. 
 
Wat spesiaal is aan die studie is dat ons inligting insamel terwyl u onder die effek van 
die spinale narkose is. Ons gaan byvoorbeeld u bloeddruk meet, vasstel hoeveel 
ongemak of pyn u ondervind, hoeveel swakheid u in u bene ondervind, sowel as hoe 
lank dit neem vir u om te herstel van die effekte van die spinale narkose. 
 
 
Wat sal gebeur indien ek besluit om nie aan hierdie studie deel te neem nie? 
 
U hoef glad nie aan hierdie studie deel te neem nie. Indien u besluit om nie hieraan 
deel te neem nie sal u nog steeds dieselfde kwaliteit sorg vir u spesifieke toestand 
ontvang, beide nou en in die toekoms. U sal steeds ‘n spinale narkose ontvang indien 
dit geskik is vir u. U mag ook besluit om op enige stadium van die studie te onttrek. 
 
 
Wat is die risiko’s vir u? 
 
Die risiko is vir u dieselfde as vir enige ander pasient wat ‘n spinale narkose 
ondergaan, en dit sal aan u verduidelik word deur die dokter wat die spinale narkose 
op u gaan doen. Sou u enige ongemak tydens die chirurgiese prosedure ondervind, sal 
die narkotiseur addisionele medisyne aan u bied. In die onwaarskynlike geval waar u 
baie ongemak mag ondervind, sal daar met algemene narkose voortgegaan moet 
word, tesame met die spinaal wat dan reeds uitgevoer is. 
 
 
Is daar enige voordele vir u om deel te neem aan hiredie studie? 
 
Daar is geen addisionele voordele vir u deur deel te neem aan hierdie studie nie. Die 
sorg en aandag wat u sal ontvang tydens hierdie prosedure is deel van roetiene 



















Die persoonlike inligting wat gekollekteer word van almal wat aan hierdie studie 
deelneem sal net gedeel word onder die dokters wat aan hierdie studie deelneem. 
Hierdie studie mag dalk in ‘n mediese joernaal gepubliseer word en die resultate van 
die groep as ‘n geheel sal gedeel word met almal wat dit lees. Daar is egter geen 
manier waarop die publiek sal kan weet wie aan die studie deelgeneem het nie. Die 
dokters wat na die resultate gaan kyk is die “ principal investigators “ wat aan die 
begin van hierdie dokument genoem is. Dit is ook belangrik dat die “ Human 
Research Ethics Committee ( HREC ) of the University of Cape Town “ toegang het 
tot die resultate van hierdie studie. Hulle doen so in gevolge hulle  regulatoriese pligte 
wat in u voordeel optree. Wees verseker dat geen bloed geneem sal word tydens 





Hiermee bevestig ek dat die dokter wat hieronder geteken het my volledig ingelig het 
omtrent die aard, prosedure, voordele en risiko’s van hierdie kliniese studie. Ek het 
ook hierdie “ PATIENT INFORMATION AND INFORMED CONSENT “ vorm 
ontvang, gelees en verstaan. Ek het genoeg geleentheid gehad om vrae te vra en ek 
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